Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
KisqaliⓇ sales grew 76% to USD 562m, with increasing
recognition of its differentiated benefit-risk profile
Sales evolution
USD m, % cc
Ex-US
US
+76%
562
US MBC NBRx share1
Rolling 3 months, %
268
23%
327
193
294
134
Q3 2022
Q3 2023
Aug 2022
Consistent efficacy
GROWTH
KISQALI
Kisqali Ph3 OS results in 1L MBC2
46%
Stage IV
HR
95% CI
MONALEESA-2 0.76
(0.63, 0.93)
MONALEESA-7
0.76
(0.61, 0.96)
MONALEESA-3
0.67
(0.50, 0.90)
Aug 2023
Consistent OS benefit across 3 Ph3 studies
NCCN guideline support as only Category 1
treatment for 1L mBC with Al³
Right Choice data showing benefit vs. doublet
chemo in aggressive HR+/HER2- MBC
Most adverse events asymptomatic
mBC
metastatic breast cancer.
NBRX-new to brand prescription.
1. Of CDK4/6 mBC market, US 3 months ending Aug 2023, IQVIA Breast Cancer Market
NCCN national comprehensive cancer network. Al aromatase inhibitor.
Sizing report. 2. MONALEESA-2: Hortobagyi et al, NEJM 2022; MONALEESA-7: Lu et al, Clin Cancer Res 2022; MONALEESA-3: Neven et al, ESMO Breast 2022. 3. NCCN Guidelines updated as of 27-Jan-2023.
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
9 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation